What is Revena?
Founded by Diogo Freitas and Mateus Noronha, Revena specializes in the deployment of generative AI agents designed to synthesize clinical histories and intricate insurance contracts. The company’s core value proposition lies in its seamless integration with existing electronic medical record (EMR) systems, enabling the automated generation of compliant medical bills. By interpreting complex payer rules in real-time, Revena significantly reduces the manual labor traditionally associated with healthcare billing, thereby enhancing operational efficiency and financial accuracy for hospital networks. The company is currently focused on the Brazilian market, where it is actively deploying its technology to streamline administrative workflows in high-volume clinical environments.
How much funding has Revena raised?
Revena has raised a total of $9M across 2 funding rounds:
Angel/Pre-Seed
$1M
Seed
$8M
Angel/Pre-Seed (2024): $1M, investors not publicly disclosed
Seed (2026): $8M led by Caravela Capital, Flourish, and Canary
Key Investors in Revena
Caravela Capital
Caravela Capital is a Brazilian venture capital firm that focuses on investing in early-stage companies across Latin America, providing the necessary capital and resources for regional growth.
Flourish
Flourish Ventures is an early-stage global venture capital firm that invests in fintech founders, focusing on mission-driven entrepreneurs and creating fair financial systems.
Canary
Canary acts as a foundational partner for top founders in Latin America, co-founding companies from the ground up with a strong community of builders.
What's next for Revena?
With this latest round of financing, Revena is well-positioned to accelerate its product roadmap and expand its footprint within the Latin American healthcare ecosystem. The strategic focus will likely shift toward deepening the capabilities of its generative AI models to handle increasingly complex insurance landscapes and expanding its integration partnerships with major hospital systems. As the company scales, the primary objective will be to maintain high levels of billing accuracy while navigating the regulatory nuances of the healthcare sector. Investors are closely watching how Revena leverages this capital to solidify its market position and drive long-term value in the healthtech vertical.
See full Revena company page
